Volume 24 Issue 3, March 2006

Editorial

The responsibilities of growing up

Editorial 01 Mar 2006

Advertisement

Top of page ⤴

News

Deconstructing Myogen's market cap

The best-performing stock from 2005 was a prime example of how biotech stocks are not as capricious as they may seem.

John Ransom
News 08 Mar 2006
Diversa restructures, raising question over bioprospecting

Diversa recently announced plans to restructure, and although officials insist that the company is not eliminating its research operations, it is certainly turning away from a rich heritage of scientific exploration.

Cormac Sheridan
News 08 Mar 2006
Toll-like receptor therapies compete to reduce side effects

An emerging class of highly specific immunomodulator drugs targeting toll-like receptors will be the focus of attention this month at a conference in Salvador, Brazil.

Charlie Schmidt
News 06 Mar 2006
Brazil and Japan give fuel to ethanol market

Rising oil prices and apprehension about global warming are prompting governments to rethink their energy supply policies.

Claudia Orellana
Ricardo Bonalume Neto
News 06 Mar 2006

Top of page ⤴

News in Brief

News In Brief

News in Brief 08 Mar 2006

Top of page ⤴

News

Profile: Robert Tjian

With a knack for attracting the right scientists, Bob Tjian set out to build a mega-biotech conglomerate. He fell short of his lofty goal, but his company was still a success.

Emily Waltz
News 08 Mar 2006

Top of page ⤴

News Feature

Finding the moral high ground

Biotech companies will be facing particular ethical challenges as their products enter the marketplace. How is the industry preparing? Ken Wilan investigates.

Ken Howard Wilan
Laura DeFrancesco
News Feature 01 Mar 2006
Where the money is

It was US investors that largely bankrolled the biotech industry over the past 25 years. Is all that about to change? Michael Fitzgerald investigates.

Michael Fitzgerald
News Feature 01 Mar 2006

Top of page ⤴

Commentary

Navigating the future(s) of biotech intellectual property

What changes, if any, can we expect in the system currently used to protect biotech inventions?

Kenneth Neil Cukier
Commentary 08 Mar 2006
Fates intertwined

Biotech will fundamentally reshape the pharmaceutical industry in the coming years. Garth Cooper, a veteran of the biotech industry, explains why.

Garth J S Cooper
Commentary 01 Mar 2006
Who took the tech out of biotech?

In recent years biotech executives have felt pressure from their investors and handlers to tone down talk of the firm's new technology because it sends the message that the company isn't sufficiently product focused. This is rubbish!

Elizabeth Silverman
Commentary 01 Mar 2006
Price controls: preparing for the unthinkable

The momentum in the United States to impose price controls is growing. Stephan Herrera lists some of the reasons why.

Stephan Herrera
Commentary 01 Mar 2006
Crystal gazing: biotech's financial outlook

A leading biotech analyst and an investment banker give their perspectives on the future of biotech.

Eric Schmidt
David J Strupp
Commentary 01 Mar 2006
The biotech analyst's view

Eric Schmidt
Commentary 01 Mar 2006
The investment banker's view

David J Strupp Jr
Commentary 01 Mar 2006
From oligos to Oprah—the consumer and biotech

Until recently, biotech firms did not concern themselves much with the complications of product advertising and corporate brand image-making. A media firm outlines the strengths of direct-to-consumer approaches; an industry commentator counters.

Paul Oestreicher
Tim Warner
John Mack
Commentary 01 Mar 2006
Point: Biotech needs direct to consumer communications

Paul Oestreicher
Tim Warner
Commentary 01 Mar 2006
Counterpoint: biotech needs more than DTC as usual

John Mack
Commentary 01 Mar 2006
Biogenerics at the crossroads

Two executives—one from a leading generics manufacturer, the other from a leading brand manufacturer—argue the pros and cons of implementing an abbreviated US regulatory framework for the approval of biogeneric products.

Carole S Ben-Maimon
Rob Garnick
Commentary 01 Mar 2006
Point: Why biogenerics make sense

Carole S Ben-Maimon
Commentary 01 Mar 2006
Counterpoint: Why biogenerics are a strawman

Rob Garnick
Commentary 01 Mar 2006
Ten years of biotech gaffes

Much of biotech's success has been built on lessons learned from mistakes. But the past ten years has also witnessed mistakes many in biotech would prefer to forget.

John Hodgson
Commentary 08 Mar 2006
Whither agbiotechnology?

What will the agbiotech landscape look like in 2016? And what form will the 'doubly green' revolution take?

L Val Giddings
Commentary 01 Mar 2006
Convergence in biomedical technology

An entrepreneur and a pioneer in innovative technologies trade views with an industry veteran on the likely importance of convergent technology in health care.

Ascher Shmulewitz
Robert Langer
John Patton
Commentary 01 Mar 2006
The ascendance of combination products

Ascher Shmulewitz
Robert Langer
Commentary 01 Mar 2006
A historical perspective on convergence technology

John S Patton
Commentary 01 Mar 2006
Welcome to the body-wide web

The coming deluge of personalized data will likely transform our health for the better. But will it also transform the way we live our lives?

David Shenk
Commentary 01 Mar 2006

Top of page ⤴

Investors Lab

A rollercoaster ride

Tom Jacobs
Investors Lab 01 Mar 2006

Top of page ⤴

Feature

Ethical decision-making in bioscience firms

A survey of the ethical practices of bioscience companies suggests that although most firms feature ethics in their mission statement or code of conduct, fewer than half of the companies surveyed have made any formal efforts to assess how well these approaches are working.

David Finegold
Allison Moser
Feature 01 Mar 2006
Who's who in biotech

Nature Biotechnology's readers select some of biotech's most remarkable and influential personalities from the past 10 years.

K S Jayaraman
Sabine Louët
Emily Waltz
Feature 02 Mar 2006
Ten years of Nature Biotechnology research

Authors of some of the most highly cited Nature Biotechnology papers from the past 10 years discuss their work and the remaining challenges for their fields.

Monya Baker
Feature 01 Mar 2006
Dawn of the gene expression array

Feature 01 Mar 2006
Proteomics goes global

Feature 01 Mar 2006
The tabula rasa of cells

Feature 01 Mar 2006
Beacons of light

Feature 01 Mar 2006
More bright ideas

Feature 01 Mar 2006
Quantum leaps

Feature 01 Mar 2006
The delivery problem

Feature 01 Mar 2006
Silence is golden

Feature 01 Mar 2006
Golden harvests

Feature 01 Mar 2006
Off the beaten path

Biotech is no longer the exclusive domain of Western economies. A group of experts from around the world discuss emerging trends and opportunities for biotech in territories outside the United States and Europe.

Jonathan Buckley
Jorge Gatica
Mark Wilson
Feature 02 Mar 2006

Top of page ⤴

Patents

Biotech patents: looking backward while moving forward

Laboratory Corporation v. Metabolite Laboratories may signal renewed interest on the part of the US Supreme Court in what is, and what is not, patentable in biology.

Rebecca S Eisenberg
Patents 01 Mar 2006
Bayh-Dole: if we knew then what we know now

More than 25 years after the US Bayh-Dole Act was passed to encourage technology transfer from universities, is it time to reexamine and revamp this key legislation?

Sara Boettiger
Alan B Bennett
Patents 01 Mar 2006

Top of page ⤴

News & Views

The selfish stem cell

Two new studies describe approaches for optimizing the culture of human embryonic stem cells.

Peter W Andrews
News & Views 01 Mar 2006
Self-illuminating quantum dots light the way

A quantum dot decorated with luciferase molecules fluoresces without external illumination.

John V Frangioni
News & Views 01 Mar 2006
Fancy footwork in the sequence space shuffle

Recent reports on directed evolution broaden the scope of evolutionary enzyme engineering.

Frances H Arnold

Collection:

Nobel Prize in Chemistry 2018
News & Views 01 Mar 2006
Know the enemy

The sequencing of 169 avian influenza virus genomes provides a much-needed boost to preparations for a pandemic.

Ee Chee Ren
News & Views 01 Mar 2006

Top of page ⤴

Analysis

Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study

David J States
Gilbert S Omenn
Samir M Hanash
Analysis 08 Mar 2006

Top of page ⤴

Letter

Self-illuminating quantum dot conjugates for in vivo imaging

Min-Kyung So
Chenjie Xu
Jianghong Rao
Letter 26 Feb 2006
Neurotrophins mediate human embryonic stem cell survival

April D Pyle
Leslie F Lock
Peter J Donovan
Letter 29 Jan 2006
CD30 is a survival factor and a biomarker for transformed human pluripotent stem cells

Daniella Herszfeld
Ernst Wolvetang
Martin F Pera
Letter 26 Feb 2006
An in vitro fluorescence screen to identify antivirals that disrupt hepatitis B virus capsid assembly

Stephen J Stray
Jennifer M Johnson
Adam Zlotnick
Letter 12 Feb 2006

Top of page ⤴

Careers and Recruitment

Aligning career ladders and the company vision

Having clearly defined job descriptions and career paths benefits both biotech companies and their employees.

Jennifer A Troia
Careers and Recruitment 01 Mar 2006

Top of page ⤴

People

People

People 01 Mar 2006

Top of page ⤴

Focus

10th Anniversary

A focus celebrating 10 years of serving the biotech community.

Focus 01 Mar 2006

Top of page ⤴

Volume 24 Issue 3, March 2006

Editorial

News

News in Brief

News

News Feature

Commentary

Investors Lab

Feature

Patents

News & Views

Analysis

Letter

Careers and Recruitment

People

Focus

Search

Quick links